Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1K23MH120351-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive disorder, OCD), worries (as seen in generalized anxiety disorder, GAD), and ruminations (as seen in major depressive disorder, MDD). Specifically, the investigators are studying whether psychological treatment can help people with RNT who have trouble stopping unwanted thoughts and shifting their attention.
The current study will examine whether enhancing attention regulation skills in a transdiagnostic intervention for repetitive negative thinking (RNT) will significantly improve the target of attentional/cognitive control. Phase 1 is an open pilot trial in which participants will be assigned to eight 60 minute sessions (over 8 weeks) of Emotion Regulation Therapy-Attention Regulation (AR-ERT). In Phase 2, participants will be randomly assigned (like the flip of a coin) to receive eight 60 minute sessions (over 8 weeks) of either: AR-ERT or Supportive Psychotherapy (SPT). The investigators will use a multi-method approach to measure attentional/cognitive control: (a) behavioral (i.e., eye tracking fixations and reaction time), (b) electrophysiological (i.e., event related potentials), and (c) self-report (i.e., perceived ability to shift and focus attention). They also will examine early signs of treatment efficacy of AR-ERT and SPT and target validation (i.e., whether changes in attentional/cognitive control correlate with changes in RNT and associated symptoms). Participants will receive assessments of these target and outcome measures at baseline (week 0), mid-treatment (week 4), post-treatment (week 8), and 3-month follow-up (week 20 - Phase 2 only). While most of these procedures are conducted virtually (e.g., therapy sessions), some (e.g., eye tracking and electrophysiological assessments) will be performed in-person. Findings could help identify a cross-cutting target that can be engaged to optimize treatment response for individuals with elevated RNT.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT) | Experimental | Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation. |
|
| Phase 2: Supportive Psychotherapy (SPT) | Active Comparator | Individuals with repetitive negative thinking receiving Supportive Psychotherapy. |
|
| Phase 1: Pilot Testing Phase | Experimental | Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Emotion Regulation Therapy - Attention Regulation (AR-ERT) | Behavioral | Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking. |
| Measure | Description | Time Frame |
|---|---|---|
| Transdiagnostic Repetitive Negative Thinking (Measured by the Perseverative Thinking Questionnaire [PTQ]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 15-item self-report measure of transdiagnostic repetitive negative thinking that includes items about thoughts as repetitive, intrusive, unproductive, and capturing mental capacity (e.g., "I think about many problems without solving any of them"). Total scores range from 0-60, with higher scores indicating more repetitive negative thinking (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Worry (Measured by the Penn State Worry Questionnaire [PSWQ]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 16-item self-report measure of the tendency to engage in excessive, uncontrollable, and generalized worry (e.g., "I am always worrying about something"). Total scores range from 16-80, with higher scores indicating more worry (i.e., worse outcomes). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ryan J Jacoby, Ph.D. | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
Not provided
| Label | URL |
|---|---|
| Attention Regulation Study website | View source |
Not provided
The investigators do not have specific plans to share individual participant data in order to preserve the confidentiality of our participants. Any data that is shared would only be done so after executing a formal Data Use Agreement from Massachusetts General Hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Phase I: 3 pilot participants were eligible and enrolled. Phase 2: 62 were eligible and randomized.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Phase 1: Pilot Testing Phase | Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation. |
| FG001 | Phase 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Phase 2 (RCT): Treatment Period |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 28, 2023 |
Not provided
Phase 1: All participants will receive AR-ERT. Phase 2: At the baseline visit, eligible participants will be randomized (1:1 in parallel) to AR-ERT or SPT.
Not provided
Not provided
Independent evaluators will remain blind to treatment condition throughout the study for all participants. Participants and study therapists will be aware which treatment they have been assigned to.
|
| Supportive Psychotherapy (SPT) | Behavioral | Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills. |
|
| Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Rumination (Measured by the Rumination Response Scale [RRS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 22-item self-report measure of the tendency to ruminate or dwell on one's distress and it's possible causes and consequences when feeling down, sad, or depressed (e.g., "Think about all your shortcomings, failings, faults, mistakes"). Total scores range from 22-88, with higher scores indicating more rumination (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Mental Rituals (Measured by the Rumination on Obsessions and Compulsions Scale [ROCS] - Mental Neutralizing Subscale) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | The ROCS is a 33-item self-report measure that assesses the frequency of various mental responses to obsessional thoughts or images in the past month with 3 sub-scales: Mental Neutralizing, Acceptance, and Rumination on OCD symptoms (no total score is used). The Mental Neutralizing Sub-Scale is 18 items and specifically assesses mental rituals including arguing with oneself, reconstructing rituals, effort against thoughts, and distraction (e.g., "I feel compelled to collect all arguments that refute the intrusive thought or image"). Total scores (which are an average of the subscale items) range from 0-4, with higher scores indicating more mental rituals (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| OCD Symptom Severity (Measured by the Yale-Brown Obsessive-Compulsive Scale [Y-BOCS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 10-item clinician-administered interview measure of past week symptom severity of obsessions and compulsions including: time, interference, distress, resistance, and control. Total scores range from 0-40, with higher scores indicating higher levels of OCD symptom severity (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Generalized Anxiety Symptom Severity (Measured by the Structured Interview Guide for the Hamilton Anxiety Rating Scale [SIGH-A]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 14-item structured, clinician-administered interview measure of past week anxiety symptom severity including: anxious mood, tension, fears, insomnia, cognitive symptoms, depressed mood, somatic (muscular, sensory) symptoms, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and observed behavior. Total scores range from 0-56, with higher scores indicating higher levels of generalized anxiety symptoms (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Depression Symptom Severity (Measured by the Structured Interview Guide for the Hamilton Depression Rating Scale [SIGH-D]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 17-item interview measure of past week depression symptom severity including: depressed mood, interest in work and activities, insomnia (early, middle, and late), genital symptoms, gastrointestinal somatic symptoms, loss of weight, general somatic symptoms, feelings of guilt, suicide, psychic anxiety, somatic anxiety, hypochondriasis, insight, agitation, retardation. Total scores range from 0-52, with higher scores indicating more depression (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| Functional Impairment (Measured by the Work and Social Adjustment Scale [WSAS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 5-item self-report scale assessing disability in work, home management, social leisure activities, private leisure activities, and the ability to form and maintain close relationships. Total scores range from 0-40, with higher scores indicating more functional impairment (i.e., worse outcomes). | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation.
| FG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Phase 2 (RCT): 3-month Follow-up |
|
|
| Phase 1: Pilot Testing |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Phase 1: Pilot Testing Phase | Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation. |
| BG001 | Phase 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT) | Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation. |
| BG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Year |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | Participants |
| ||||||||||||||||
| Education | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Transdiagnostic Repetitive Negative Thinking (Measured by the Perseverative Thinking Questionnaire [PTQ]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 15-item self-report measure of transdiagnostic repetitive negative thinking that includes items about thoughts as repetitive, intrusive, unproductive, and capturing mental capacity (e.g., "I think about many problems without solving any of them"). Total scores range from 0-60, with higher scores indicating more repetitive negative thinking (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, a few more did not complete this self-rated questionnaire despite completing other measures at the same timepoint. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Worry (Measured by the Penn State Worry Questionnaire [PSWQ]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 16-item self-report measure of the tendency to engage in excessive, uncontrollable, and generalized worry (e.g., "I am always worrying about something"). Total scores range from 16-80, with higher scores indicating more worry (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, a few more did not complete this self-rated questionnaire despite completing other measures at the same timepoint. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Rumination (Measured by the Rumination Response Scale [RRS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 22-item self-report measure of the tendency to ruminate or dwell on one's distress and it's possible causes and consequences when feeling down, sad, or depressed (e.g., "Think about all your shortcomings, failings, faults, mistakes"). Total scores range from 22-88, with higher scores indicating more rumination (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, a few more did not complete this self-rated questionnaire despite completing other measures at the same timepoint. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mental Rituals (Measured by the Rumination on Obsessions and Compulsions Scale [ROCS] - Mental Neutralizing Subscale) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | The ROCS is a 33-item self-report measure that assesses the frequency of various mental responses to obsessional thoughts or images in the past month with 3 sub-scales: Mental Neutralizing, Acceptance, and Rumination on OCD symptoms (no total score is used). The Mental Neutralizing Sub-Scale is 18 items and specifically assesses mental rituals including arguing with oneself, reconstructing rituals, effort against thoughts, and distraction (e.g., "I feel compelled to collect all arguments that refute the intrusive thought or image"). Total scores (which are an average of the subscale items) range from 0-4, with higher scores indicating more mental rituals (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, a few more did not complete this self-rated questionnaire despite completing other measures at the same timepoint. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | OCD Symptom Severity (Measured by the Yale-Brown Obsessive-Compulsive Scale [Y-BOCS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 10-item clinician-administered interview measure of past week symptom severity of obsessions and compulsions including: time, interference, distress, resistance, and control. Total scores range from 0-40, with higher scores indicating higher levels of OCD symptom severity (i.e., worse outcomes). | Only participants who had symptoms of OCD completed the Y-BOCS (n=35 out of 62). Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Generalized Anxiety Symptom Severity (Measured by the Structured Interview Guide for the Hamilton Anxiety Rating Scale [SIGH-A]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 14-item structured, clinician-administered interview measure of past week anxiety symptom severity including: anxious mood, tension, fears, insomnia, cognitive symptoms, depressed mood, somatic (muscular, sensory) symptoms, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and observed behavior. Total scores range from 0-56, with higher scores indicating higher levels of generalized anxiety symptoms (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, one participant dropped out of the study after completing week 4 self-rated questionnaires and before completing this clinician-rated measure. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Depression Symptom Severity (Measured by the Structured Interview Guide for the Hamilton Depression Rating Scale [SIGH-D]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 17-item interview measure of past week depression symptom severity including: depressed mood, interest in work and activities, insomnia (early, middle, and late), genital symptoms, gastrointestinal somatic symptoms, loss of weight, general somatic symptoms, feelings of guilt, suicide, psychic anxiety, somatic anxiety, hypochondriasis, insight, agitation, retardation. Total scores range from 0-52, with higher scores indicating more depression (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, one participant dropped out of the study after completing week 4 self-rated questionnaires and before completing this clinician-rated measure. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Functional Impairment (Measured by the Work and Social Adjustment Scale [WSAS]) Assessed in Phase I (Pilot Trial) and Group Differences Compared at 8 Weeks in Phase 2 Randomized Controlled Trial | 5-item self-report scale assessing disability in work, home management, social leisure activities, private leisure activities, and the ability to form and maintain close relationships. Total scores range from 0-40, with higher scores indicating more functional impairment (i.e., worse outcomes). | Intent-to-treat analysis, which included all participants randomized to each treatment arm. Some participants dropped out prior to completion of the mid-treatment (week 4), end-of-treatment (week 8), or 3-month follow-up (week 20) assessments (see participant flow chart). Finally, a few more did not complete this self-rated questionnaire despite completing other measures at the same timepoint. | Posted | Mean | Standard Deviation | score on a scale (by group) | Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up) |
|
Week 0 (baseline), week 4 (mid-treatment), week 8 (post-treatment), and week 20 (3-month follow-up)
Participants were asked 4 questions about: (1) any major physical health problems or major physical injuries; (2) seeing a physical health or mental health provider for any reason; (3) any hospitalizations; or (4) any other major problems or concerns, all pertaining to the time since they were assessed last. Any "yes" resulted in further inquiries into specific adverse events.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Phase 1: Pilot Testing Phase | Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation | 0 | 3 | 0 | 3 | 1 | 3 |
| EG001 | Phase 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT) | Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation. | 0 | 31 | 0 | 31 | 16 | 31 |
| EG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. | 0 | 31 | 0 | 31 | 12 | 31 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cold/Flu/COVID | Infections and infestations | Systematic Assessment |
| ||
| EEG discomfort | General disorders | Systematic Assessment |
| ||
| Hip, neck, back, foot/ankle injury or stiffness or tendonitis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Increased depression/anxiety/stress | Psychiatric disorders | Systematic Assessment |
| ||
| Migraine | Nervous system disorders | Systematic Assessment |
| ||
| Yeast infection / UTI | Infections and infestations | Systematic Assessment |
| ||
| Allergies | Immune system disorders | Systematic Assessment |
| ||
| Kidney failure | Renal and urinary disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ryan J. Jacoby, Ph.D. | Massachusetts General Hospital | 617-724-4167 | rjjacoby@mgh.harvard.edu |
| Feb 11, 2026 |
| Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jun 21, 2023 | Feb 11, 2026 | ICF_001.pdf |
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| D000098647 | Generalized Anxiety Disorder |
| D003865 | Depressive Disorder, Major |
| D000079562 | Rumination Syndrome |
| D009770 | Obsessive Behavior |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D001068 | Feeding and Eating Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Some college |
|
| College graduate |
|
| Graduate or professional school |
|
| Week 4 |
|
|
| Week 8 |
|
|
| Week 20 |
|
|
| Superiority |
| Null hypothesis: there is no significant difference in the change from baseline to end-of-treatment PTQ-PW scores between the treatment groups. | Mixed Models Analysis | Repeated measures were modeled with a first-order heterogeneous auto-regressive (ARH(1)) covariance structure. | 0.095 | The p-value was not adjusted for multiple comparisons. The a priori threshold for statistical significance was alpha=.05. | Difference in the amount of change | -4.781 | 2-Sided | 95 | -10.401 | 0.840 | The effect is presented as the difference in the amount of symptom reduction (week 8 - week 0) between the AR-ERT group and the SPT group (i.e., a group difference in the amount of change over time). | Superiority |
| Phase 2: Supportive Psychotherapy (SPT) |
Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
| OG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
| OG001 |
| Phase 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT) |
Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation. |
| OG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
| OG002 |
| Phase 2: Supportive Psychotherapy (SPT) |
Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation. |
| OG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
Individuals with repetitive negative thinking randomized to Emotion Regulation Therapy - Attention Regulation. |
| OG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|
| OG002 | Phase 2: Supportive Psychotherapy (SPT) | Individuals with repetitive negative thinking randomized to Supportive Psychotherapy. |
|
|
|